Johnson & Johnson Debt to Equity Ratio 2006-2018 | JNJ

Current and historical debt to equity ratio values for Johnson & Johnson (JNJ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Johnson & Johnson debt/equity for the three months ending September 30, 2018 was 0.46.
Johnson & Johnson Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $29.48B $64.63B 0.46
2018-06-30 $29.41B $62.89B 0.47
2018-03-31 $29.84B $63.26B 0.47
2017-12-31 $30.68B $60.16B 0.51
2017-09-30 $26.68B $73.98B 0.36
2017-06-30 $27.36B $71.92B 0.38
2017-03-31 $27.02B $70.34B 0.38
2016-12-31 $22.44B $0.00B 0.00
2016-09-30 $23.55B $72.77B 0.32
2016-06-30 $24.54B $72.47B 0.34
2016-03-31 $20.23B $72.65B 0.28
2015-12-31 $12.86B $0.00B 0.00
2015-09-30 $14.07B $71.55B 0.20
2015-06-30 $14.09B $71.13B 0.20
2015-03-31 $14.94B $67.88B 0.22
2014-12-31 $15.12B $69.75B 0.22
2014-09-30 $13.15B $76.59B 0.17
2014-06-30 $13.30B $78.05B 0.17
2014-03-31 $13.34B $76.58B 0.17
2013-12-31 $13.33B $74.05B 0.18
2013-09-30 $9.75B $69.80B 0.14
2013-06-30 $9.64B $69.67B 0.14
2013-03-31 $11.36B $66.86B 0.17
2012-12-31 $11.49B $64.83B 0.18
2012-09-30 $11.43B $63.76B 0.18
2012-06-30 $11.53B $60.43B 0.19
2012-03-31 $13.01B $61.37B 0.21
2011-12-31 $12.97B $57.08B 0.23
2011-09-30 $13.03B $61.53B 0.21
2011-06-30 $13.68B $62.13B 0.22
2011-03-31 $9.26B $59.86B 0.16
2010-12-31 $9.16B $56.58B 0.16
2010-09-30 $9.18B $57.29B 0.16
2010-06-30 $7.94B $52.85B 0.15
2010-03-31 $8.06B $52.91B 0.15
2009-12-31 $8.22B $50.59B 0.16
2009-09-30 $8.26B $50.38B 0.16
2009-06-30 $8.18B $46.25B 0.18
2009-03-31 $8.05B $43.79B 0.18
2008-12-31 $8.12B $42.51B 0.19
2008-09-30 $8.40B $45.73B 0.18
2008-06-30 $8.77B $46.44B 0.19
2008-03-31 $7.17B $45.63B 0.16
2007-12-31 $7.07B $43.32B 0.16
2007-09-30 $4.63B $43.57B 0.11
2007-06-30 $2.01B $43.12B 0.05
2007-03-31 $2.01B $40.93B 0.05
2006-12-31 $2.01B $39.32B 0.05
2006-09-30 $2.01B $40.57B 0.05
2006-06-30 $1.98B $40.74B 0.05
2006-03-31 $1.98B $41.12B 0.05
2005-12-31 $2.02B $38.71B 0.05
2005-09-30 $2.14B $36.85B 0.06
2005-06-30 $2.33B $35.17B 0.07
2005-03-31 $2.46B $33.65B 0.07
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $390.174B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $261.450B 14.74
Merck (MRK) United States $206.852B 17.92
Novartis AG (NVS) Switzerland $201.155B 17.24
AbbVie (ABBV) United States $130.807B 11.61
Eli Lilly (LLY) United States $120.318B 21.15
Novo Nordisk (NVO) Denmark $110.887B 18.01
Sanofi (SNY) France $109.052B 13.50
AstraZeneca (AZN) United Kingdom $96.706B 12.01
GlaxoSmithKline (GSK) United Kingdom $92.502B 12.43
Bristol-Myers Squibb (BMY) United States $86.637B 14.27